Navigation Links
MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
Date:10/16/2007

WELLESLEY HILLS, Mass., Oct. 16 /PRNewswire-FirstCall/ -- MacroChem (OTC Bulletin Board: MACM) will participate in the PIPEs Conference 2007 to be held at the Hilton New York on October 18 and 19. The company will have an exhibit table, located outside the Sutton Room, throughout each day of the conference. MacroChem's President and Chief Executive Officer, Robert J. DeLuccia, will provide a company overview, including discussion about MacroChem's lead product, EcoNail(R), which is currently in a fully enrolled Phase 2 clinical trial. DeLuccia will also discuss MacroChem's newly acquired rights to pexiganan, a novel, topical anti-infective drug for treatment of diabetic foot infection (DFI), and its recent preferred stock conversion and private placement.

The PIPEs Conference will be a mix of education and networking with active investors in the small cap equity market. Two full days of programming will provide insight on industry developments from experts in the field, as well as networking opportunities with institutional investors, investment bankers, corporate attorneys, company executives, financial analysts, and media representatives from around the globe.

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Our lead product candidate is EcoNail, a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. We recently acquired exclusive worldwide license rights to pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, which has already completed two Phase 3 trials. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. Our pipeline of clinical-stage and early-stage product candidates is based on our SEPA(R), MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For more information visit our website, http://www.macrochem.com.

Forward-Looking Statements

With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com.

Contact:

MacroChem: Bernard Patriacca -- VP/CFO

bpatriacca@macrochem.com, (781) 489-7310

Investor Relations: The Investor Relations Group, Inc.

Christine Berni / Joseph Triunfo, (212) 825-3210

cberni@investorrelationsgroup.com, jtriunfo@investorrelationsgroup.com

Media:

Bill Douglass / Michaela Heller, (212) 825-3210

bdouglass@investorrelationsgroup.com

mheller@investorrelationsgroup.com


'/>"/>
SOURCE MacroChem Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Bruker Participates in Dutch Funded Super Microscope Project
2. Digital Healthcare Conference 2007: Mounting obstacles for health IT
3. Biomedical engineering conference invites manufacturers
4. Conference to address small town development
5. Wisconsin to host SBIR Conference
6. Gaming conference explores interactive media in learning
7. Digital Healthcare Conference starts on a realistic note
8. Digital Healthcare Conference marks Wisconsins Healthcare IT Week
9. Third coast of biotechnology makes strong showing at VC conference
10. Why companies dont get invited to the DEMO conference
11. Giuliani will keynote RedPrairie Corporations user conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... -- According to a new market report published ... A Streptococcus (GAS) Nucleic Acid (NA) Test Products Market - ... - 2023 ", the Europe molecular ... test products market was valued at US$ 8.3 Mn in ... 11.6% from 2015 to 2023 to reach US$ 22.3 Mn ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... release, Clinical Studio Version 4.1, greatly improves performance of the platform. In particular, ... often generate tremendous volumes of data to be collected on a per patient ...
(Date:5/5/2016)... ... 2016 , ... Proove Biosciences, Inc. today announced ... diagnostics company. The Algynomics platform and its patient cohorts provide researchers ... chronic pain, which will allow targeted preventive efforts, enhance patient stratification in clinical ...
(Date:5/5/2016)...  Why are two uber-successful former agency presidents ... launching a new venture—yet going about things in a ... helping clients raise the value of their offerings in ... type of collaboration. The result is Elevate, ... medical device sectors. Elevate specializes in shaping and transforming ...
Breaking Biology Technology:
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/17/2016)... , March 17, 2016 ABI ... intelligence, forecasts the global biometrics market will reach ... impressive 118% increase from 2015. Consumer electronics, particularly ... embedded fingerprint sensors anticipated to reach two billion ... Dimitrios Pavlakis , Research Analyst at ...
(Date:3/11/2016)... , March 11, 2016 http://www.apimages.com ) ... Cross reference: Picture is available at AP Images ( http://www.apimages.com ) ... DERMALOG will be used to produce the new refugee identity cards. ... biometric innovations, at CeBIT in Hanover next ... from DERMALOG will be used to produce the new refugee identity ...
Breaking Biology News(10 mins):